Antiviral activity of amenamevir alone and in combination with ganciclovir against equine herpesvirus 1

Yoshinori Kambayashi, Erika S. Hue, Camille Normand, Christine Fortier, Thomas Barnoux, Hiroshi Bannai, Koji Tsujimura, Manabu Nemoto, Nanako Kawanishi, Guillaume Fortier, Stéphane Pronost
Antiviral Research · Elsevier · DOI: 10.2139/ssrn.7293349

Аннотация

Equine herpesvirus 1 (EHV-1) causes respiratory disease, abortion, and equine herpesvirus myeloencephalopathy (EHM), a neurological disorder characterized by ataxia and hindlimb paralysis. Although EHM remains a major concern in the equine industry, effective antiviral treatment options are limited. This study evaluated the antiviral activity of amenamevir, a helicase-primase complex inhibitor, against multiple EHV-1 strains using the real-time cell analysis (RTCA) eSight system and quantitative PCR (qPCR), and compared its potency with those of ganciclovir, acyclovir, and penciclovir. Eight EHV-1 strains associated with different clinical manifestations and characterized by A, G, or C at position 2254 of ORF30 were examined. RTCA-based half-maximal inhibitory concentration (IC50) values were calculated from inhibition rates based on the area under the normalized cell index curve. Across the eight strains, IC50 values ranged from 0.45 to 2.31 µg/mL for amenamevir, 0.45 to 3.95 µg/mL for ganciclovir, 17.93 to 50.15 µg/mL for acyclovir, and 8.38 to 24.52 µg/mL for penciclovir. qPCR analysis, based on the concentrations required to achieve a 1-log10 reduction in viral genome copy number, showed a similar overall trend. Amenamevir therefore exhibited in vitro antiviral activity against EHV-1, with potency comparable to that of ganciclovir and greater than those of acyclovir and penciclovir. Combination analysis using SynergyFinder showed synergistic interactions between amenamevir and ganciclovir within selected concentration ranges against EHV-1 strains in both the Bliss independence and ZIP models. These findings support further investigation of amenamevir, alone and in combination with ganciclovir, as a candidate antiviral compounds for the treatment of EHV-1 infection.

Читать у издателя →

Похожие статьи